CSL Behring has announced that IDELVION® (coagulation factor IX recombinant, rFIX-FP) its long-acting recombinant albumin fusion protein for treating hemophilia B is now available in a 3500 IU (international unit) vial size. This new vial size will reduce the reconstitution time that was needed to prepare multiple vials for a similar dose.
“This enhancement to our IDELVION® family of products represents our focus on patients and our commitment to help hemophilia patients lead full lives,” said Bob Lojewski, senior vice president and general manager, North America Commercial Operations, at CSL Behring.
Source: CSL Behring press release dated August 18, 2018